Market Intelligence, Clinical Progress, and High-Purity Reagents for Cancer Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MAGEB16 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MAGEB16 Full-Length Recombinant Protein HEK293 Expressed (Native Conformation), High Purity (>95%), Endotoxin <1 EU/µg, Sequence Verified via Mass Spec |
View MAGEB16 Products |
| Gene Delivery | MAGEB16 Premade Lentivirus Particles Full-length ORF with Puromycin selection marker for stable cell line generation, Titer >10⁸ TU/mL |
View MAGEB16 Products |
| Benchmark Ab | Anti-MAGEB16 Monoclonal Antibody (Clone R&D Grade) Rabbit/Mouse chimeric, Recombinant expression, Suitable for IHC/Flow cytometry validation |
View MAGEB16 Products |
| Validator | MAGEB16 siRNA Set (3 unique sequences) Chemically synthesized, HPLC purified, for knockdown specificity verification |
View MAGEB16 Products |
| Related Target A | MAGEA1 (MAGE Family A1) High sequence homology - Essential for cross-reactivity screening |
View MAGEA1 Products |
| Related Target B | MAGEB2 (MAGE Family B2) Closest paralog - Critical for specificity validation assays |
View MAGEB2 Products |
| Related Target C | CTAG1B / NY-ESO-1 Co-expressed Cancer-Testis Antigen - Synergistic immunotherapy target |
View CTAG1B Products |
| Related Target D | MAGE-A4 Clinically validated with approved TCR-T; essential for homology counter-screening |
View MAGE-A4 Products |
| Related Target E | HLA-A*02:01 Essential MHC Class I molecule for intracellular peptide presentation |
View HLA-A Products |
| Related Target F | MAGEA3 Homologous Cancer-Testis Antigen for cross-reactivity screening |
View MAGEA3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Preclinical Evaluation (Human vs Cyno) | Human/Cynomolgus Monkey MAGEB16 Ortholog Proteins available with >95% purity, Sequence Verified |
| MAGE Family Homology / Off-target Cross-reactivity | Homolog Panel Proteins (MAGEA1, MAGEB2, MAGE-A4, MAGEA3) strictly verified by Mass Spec for epitope specificity assays |
| Intracellular Target Validation & Presentation | Lentivirus particles for stable overexpression in tumor cell lines (MCF-7, A375) enabling Flow/IHC validation; native sequences preserved for accurate MHC-multimer construction |
| Lack of Validated Assay Controls | Sequence-verified anti-MAGEB16 recombinant antibody included for detection and pulldown controls; clinical benchmark antibodies for IHC/Western Blot |
| False Positive Control in Functional Assays | Validated siRNA Set included for high-stringency specificity confirmation via knockdown rescue |
Live MAGEB16 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The resurgence of Cancer-Testis Antigens (CTAs) in immuno-oncology has positioned MAGEB16 as an emerging target for next-generation TCR-T cell therapies and personalized cancer vaccines. Unlike the heavily exploited MAGE-A subfamily, MAGEB16 offers novel epitope opportunities with reduced central tolerance concerns. Notably, MAGEB16 harbors key genetic variations (dbSNP:rs1410961, rs1410962, rs5973488) that may influence immunogenicity and epitope selection. As first-generation agents enter preclinical validation, the differentiation battleground centers on epitope specificity—avoiding cross-reactivity with the highly homologous MAGE-B subfamily while maximizing tumor-restricted expression recognition.
The race for MAGEB16 therapeutics is intensifying, with major players shifting focus from traditional chemotherapy to T-cell receptor-engineered therapies, mRNA vaccine platforms, and TCR-mimic bispecifics. As first-generation therapies reach the clinic, the next wave of R&D is targeting combination strategies with checkpoint inhibitors, resistance mutation profiling, and optimal peptide-MHC binding kinetics to conquer solid tumors.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| TCR-T Cell Therapy | Adaptimmune, TCR2 Therapeutics, Immatics, Emerging biotechs | Melanoma, NSCLC, Bladder Cancer, Urothelial Carcinoma | Peptide-MHC Binding Assay (need high-purity MAGEB16 protein for pulsing); Cross-reactivity panel (need MAGE family ortholog proteins); Stable target expression (need Lentivirus) |
| Cancer Vaccines (mRNA/Peptide) | BioNTech, Moderna, Immatics | Metastatic Melanoma, Solid Tumors | Immunogenicity Screening (need endotoxin-controlled protein <1 EU/µg for DC pulsing and ELISpot) |
| Bispecific Antibodies (incl. TCR-Mimic) | Amgen, Roche (Genentech), Immunocore | Solid Tumors, Refractory Cancers | Cross-reactivity Panel (need MAGEA1/MAGEB2/MAGEA3 proteins for specificity); Affinity tuning (need perfectly synthesized pMHC complexes) |
| Adoptive Cell Transfer | NIH/NCI, Academic Centers | Renal Cell Carcinoma | Tumor Cell Line Engineering (need MAGEB16 Lentivirus for stable expression in HLA-matched lines) |